Literature DB >> 16464653

Low serum levels of 25-hydroxy vitamin D in adults affected by thalassemia major or intermedia.

N Napoli1, Enrico Carmina, Salvatore Bucchieri, C Sferrazza, G B Rini, G Di Fede.   

Abstract

Adult thalassemic patients have reduced bone mass due to disturbances in several different mechanisms affecting bone turnover. To determine if vitamin D deficiency contributes to the low bone mass of adult thalassemic subjects, we studied serum 25-OH-vitamin D levels in 90 patients (age ranging between 21 and 48 years) affected with thalassemia major (TM) and 35 (age 21-56 years) with thalassemia intermedia (TI). TM patients had been receiving regular transfusions from the age of 2 years and had increased serum ferritin, glutamic oxalacetic transaminase, glutamic piruvic transaminase as well as low bone density (L1-L4 Z score -2.07 +/- 0.2). TI patients did not receive transfusions, but their ferritin levels were increased as well (520.3 +/- 138,1). 8 TM patients (10.1%) and 4 TI (11.4%) had serum 25-OH-vitamin D less than 10.4 ng/ml and were considered presenting an absolute deficiency of vitamin D. Mean 25-OH-vitamin D was significantly (P < 0.01) lower in both TM and TI patients (20.3 +/- 0.7 ng/ml and 20.9 +/- 2.3 ng/ml, respectively) than in 100 healthy control subjects of similar age (25.2 +/- 1 ng/ml). 1,25-OH-vitamin D levels were in the normal-lower levels (45.15 +/- 1.5 mg/dl), while 24 H urinary calcium was below the normal range (15.75 mg/dl). In TM patients, the 25-OH-vitamin D levels correlated negatively with age (P < 0.05) and with serum ferritin (P < 0.05). TM and TI patients with low 25-OH-vitamin D levels (<17.8 ng/ml) presented higher serum ferritin levels (P < 0.01) and higher PTH (P < 0.05) compared to those with normal vitamin D. Moreover, TM patients with low 25-OH-vitamin D levels were significantly older (P < 0.05) and had higher GPT (P < 0.05) than patients with normal vitamin D. In conclusion, calcium metabolism is frequently impaired in adult thalassemic patients. An early and effective medical treatment should be taken in consideration by the clinician in order to improve the bone health in these patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16464653     DOI: 10.1016/j.bone.2005.11.018

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  32 in total

Review 1.  β-thalassemia intermedia: a clinical perspective.

Authors:  Khaled M Musallam; Ali T Taher; Eliezer A Rachmilewitz
Journal:  Cold Spring Harb Perspect Med       Date:  2012-07       Impact factor: 6.915

2.  A 2-year prospective densitometric study on the influence of Fok-I gene polymorphism in young patients with thalassaemia major.

Authors:  M Dimitriadou; A Christoforidis; L Fidani; M Economou; E Vlachaki; M Athanassiou-Metaxa; G Katzos
Journal:  Osteoporos Int       Date:  2015-08-15       Impact factor: 4.507

3.  Are Serum Levels of F2-Isoprostane and Oxidized-LDL Related to Vitamin D Status in Type 2 Diabetic Patients? A Case-Control Study.

Authors:  Mohammad Hassan Javanbakht; Hamed Mohammady; Koorosh Fooladsaz; Maryam Razzaghi; Mahnaz Zarei; Mahmoud Djalali
Journal:  Rep Biochem Mol Biol       Date:  2016-10

4.  Role of CYP24A1, VDR and GC gene polymorphisms on deferasirox pharmacokinetics and clinical outcomes.

Authors:  S Allegra; J Cusato; S De Francia; A Arduino; F Longo; E Pirro; D Massano; A De Nicolò; A Piga; A D'Avolio
Journal:  Pharmacogenomics J       Date:  2017-11-21       Impact factor: 3.550

5.  Parathyroid and calcium status in patients with thalassemia.

Authors:  Meenu Goyal; Pankaj Abrol; Harbans Lal
Journal:  Indian J Clin Biochem       Date:  2010-09-14

6.  Interdependence of cardiac iron and calcium in a murine model of iron overload.

Authors:  Maya Otto-Duessel; Casey Brewer; John C Wood
Journal:  Transl Res       Date:  2010-12-13       Impact factor: 7.012

7.  Differences in the prevalence of growth, endocrine and vitamin D abnormalities among the various thalassaemia syndromes in North America.

Authors:  Maria G Vogiatzi; Eric A Macklin; Felicia L Trachtenberg; Ellen B Fung; Angela M Cheung; Elliott Vichinsky; Nancy Olivieri; Melody Kirby; Janet L Kwiatkowski; Melody Cunningham; Ingrid A Holm; Martin Fleisher; Robert W Grady; Charles M Peterson; Patricia J Giardina
Journal:  Br J Haematol       Date:  2009-07-13       Impact factor: 6.998

8.  Vitamin D Receptor (VDR) Gene Polymorphisms (FokI, BsmI) and their Relation to Vitamin D Status in Pediatrics βeta Thalassemia Major.

Authors:  Shereen Mohamed Elhoseiny; Dalia Saber Morgan; Asmaa Mohamed Rabie; Samer Tharwat Bishay
Journal:  Indian J Hematol Blood Transfus       Date:  2015-05-19       Impact factor: 0.900

Review 9.  Thalassemia-associated osteoporosis: a systematic review on treatment and brief overview of the disease.

Authors:  A D Dede; G Trovas; E Chronopoulos; I K Triantafyllopoulos; I Dontas; N Papaioannou; S Tournis
Journal:  Osteoporos Int       Date:  2016-08-08       Impact factor: 4.507

10.  Fracture prevalence and relationship to endocrinopathy in iron overloaded patients with sickle cell disease and thalassemia.

Authors:  Ellen B Fung; Paul R Harmatz; Meredith Milet; Thomas D Coates; Alexis A Thompson; Mark Ranalli; Robert Mignaca; Charles Scher; Patricia Giardina; Shanda Robertson; Lynne Neumayr; Elliott P Vichinsky
Journal:  Bone       Date:  2008-03-15       Impact factor: 4.398

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.